AI applications across clinical trials including patient recruitment, protocol design, site selection, biomarker identification, and adaptive trial modeling.
AI clinical trial site selection: how to find the right sites before your competitor does 30% of clinical trial sites enrol zero patients. That statistic has not changed materially in two decades despite decades of site selection process improvement. The fundamental problem is that traditional site selection is relationship-driven and backward-looking. AI is changing both […]
AI Patient Recruitment Optimization in Clinical Trials: Fixing the Problem That Kills Half Your Development Timeline Eighty percent of clinical trials fail to meet their recruitment targets. Nearly a third of all Phase III studies fail to enroll a single patient on time. Recruitment delays extend trial timelines by an average of six to eight
AI Patient Recruitment Optimization: Fix the Problem That Kills Half Your Timeline Read More »
One Injection Restored Hearing in Every Patient. What Gene Therapy Just Did to the Rare Disease Market A single injection. Ten patients. Every one of them heard sounds they had never heard before. This is not a promising early result. This is a signal the rare disease commercial model is about to change. Slide 1
One Injection Restored Hearing in Every Patient. What Gene Therapy Just Changed. Read More »
In the week of March 29 to April 5, 2026, four simultaneous signals confirmed that AI is compressing every layer of the biotech value chain at once. Insilico Medicine published Phase IIa results for the first wholly AI-designed drug. NVIDIA expanded BioNeMo for life sciences. Tempus AI reported a 27% improvement in trial patient identification. EvolutionaryScale released ESM Cambrian. The cumulative effect on development timelines and commercial NPV is multiplicative, not additive.
AI Is Compressing Every Layer of Biotech at the Same Time Read More »
